Shilpa Gupta, MD

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Dr. Shilpa Gupta is a genitourinary oncologist at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.

Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Gupta was a faculty at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics from 2011 until 2015. From 2015 until 2019, she was staff and Lead for the Solid Tumor Phase 1 Program at Masonic Cancer Center, University of Minnesota. Dr. Gupta serves on the ASCO Annual Scientific Committee for Genitourinary Cancers and SITC Anti-PD-1/PD-L1 Resistance Task Force. She is also on the panel of the SITC Cancer Immunotherapy Guidelines and has been appointed to the International Bladder Cancer Groups’ core committee and Society of International Urology Innovators.

Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer.  Dr. Gupta led several early and late phase clinical trials in bladder cancer. She is Principal Investigator of the 2020 Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and the Co-Principal Investigator of the Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is also actively working on integrating pathomics and radiomics to identify biomarkers of response and resistance in bladder cancer. Finally, Dr. Gupta is studying effect of host factors like microbiome and role of antibiotics on the efficacy of immunotherapy in bladder cancer.